ProQR Therapeutics (PRQR) Expected to Post Quarterly Earnings on Thursday

ProQR Therapeutics (NASDAQ:PRQR) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect ProQR Therapeutics to post earnings of ($0.14) per share and revenue of $4.5610 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 12:30 PM ET.

ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%.The firm had revenue of $2.35 million for the quarter, compared to the consensus estimate of $5.19 million. On average, analysts expect ProQR Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ProQR Therapeutics Stock Performance

Shares of PRQR opened at $1.73 on Thursday. ProQR Therapeutics has a 52-week low of $1.33 and a 52-week high of $3.10. The firm has a market cap of $182.27 million, a price-to-earnings ratio of -3.46 and a beta of 0.04. The business’s fifty day moving average is $1.66 and its 200-day moving average is $1.64.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. JonesTrading reduced their price objective on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Weiss Ratings lowered shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Wall Street Zen cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Finally, Chardan Capital decreased their target price on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Insider Transactions at ProQR Therapeutics

In other news, Director Bart Filius purchased 150,000 shares of the business’s stock in a transaction dated Friday, July 17th. The shares were purchased at an average cost of $1.72 per share, with a total value of $258,000.00. Following the completion of the purchase, the director owned 300,000 shares of the company’s stock, valued at $516,000. This trade represents a 100.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Boer Daniel Anton De purchased 150,000 shares of ProQR Therapeutics stock in a transaction dated Thursday, July 9th. The shares were purchased at an average price of $1.74 per share, for a total transaction of $261,000.00. Following the completion of the acquisition, the chief executive officer owned 300,000 shares of the company’s stock, valued at approximately $522,000. The trade was a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 600,000 shares of company stock worth $988,500 over the last three months. Insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. increased its position in ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 4,500 shares during the period. Guggenheim Capital LLC acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth $35,000. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth $51,000. Simplex Trading LLC grew its stake in shares of ProQR Therapeutics by 44,169.0% in the fourth quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock worth $89,000 after purchasing an additional 44,169 shares during the last quarter. Finally, Persistent Asset Partners Ltd grew its stake in shares of ProQR Therapeutics by 24.5% in the fourth quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 8,874 shares during the last quarter. 32.65% of the stock is owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.